银屑病关节炎小鼠模型 z-bo 2020-10-26 602

　　Psoriatic arthritis (PsA) is a chronic inflammatory disease that reduces the patient's mobility and flexibility. It is well known that PsA can increase the risk of type 2 diabetes. A recent study published in the journal FASEB tested a new type of mouse model that could eventually be used to treat human skin conditions, joint lateral and intervertebral disc degeneration, thereby improving the quality of life of PsA patients. To do this, the researchers used two groups of non-obese diabetic (NOD) mice.

　　"One group was infected with adenovirus vectors capable of expressing single-chain IL-23 (inflammation-inducing cytokine), and the other group was infected with a control virus. After a single intravenous injection, people infected with the IL-23 virus will produce PsA. The systemic spread of the virus has caused a series of common symptoms in PsA patients, including skin, intervertebral disc herniation and joint diseases. Due to the occurrence of these symptoms, this is the only mouse PsA model. Paulobbins, professor of biochemistry, molecular biology, and biophysics at the University of Minnesota, said: "This new mouse model represents a good human PsA model, which includes most of the symptoms of human diseases. This model can detect and optimize PsA. Treat and improve the quality of life of PsA patients. In another surprising discovery, the research team observed that IL-23 does not accelerate the onset of diabetes, but it delays hyperglycemia or hyperglycemia.

　　Dr. Thoru Pederson, editor-in-chief of FASEB magazine, said: "This disease has long required a powerful animal model system. This research is a major improvement."